Default company panoramic image
173c42bc 6347 43f9 b931 8df3f1a55bb9

Aristea Translational Medicine Corp

Aims are commercialization of a patent pending drug for Concussion and prevention of secondary Chronic Traumatic Encephalopathy and Alzheimer's disease .

  • Stage Product In Development
  • Industry Biotechnology
  • Location Park City, UT, US
  • Currency USD
  • Founded May 2012
  • Employees 1
  • Website aristeatranslationalmedicine.com

Company Summary

Aristea has developed a drug with demonstrated effectiveness against Concussion (mild Traumatic Brain Injury) in a mouse model. No drug treatment can currently reduce the pathology following Concussion or the increased risks of later onset Chronic Traumatic Encephalopathy or Alzheimer's disease. With extensive human safety already demonstrated our drug is ready to enter clinical trials. A patent is pending.

Team

  • Default avatar
    Robert E Becker
    President

    Academic psychiatrist and clinical pharmacologist Has previously developed and patented a drug licensed for commercialization by a major international pharmaceutical firm.